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Background
Obstructive sleep apnea (OSA) is a common disease in the general population. 
Obesity is a strong risk factor of OSA and its prevalence is continuously increasing 
with an estimated number of 1.1 billion obese individuals (BMI>30 kg/m2) by 2030. 
Bariatric surgery is an intervention that produces substantial and sustained weight 
loss in adults. Due to the increased peri- and postoperative risk in these patients an 
assessment for sleep apnoea prior to bariatric surgery is recommended. 
The aim of this retrospective cohort study was to investigate prevalence and 
independent predictive factors of OSA (AHI>5/h) in obese patients prior to bariatric 
surgery in a single university centre.
We analysed data of all morbidly obese patients (BMI>35 kg/m2) who underwent a 
home respiratory polygraphy prior to bariatric surgery between January 2012 to July 
2015. Additional demographic data, laboratory values, pulmonary function testing 
and data from sleep questionnaires (STOPBang, Epworth Sleepiness Scale, Fatigue 
Severity Scale) were analysed. 
All data are reported descriptively using median together with  interquartile range.  
Sensitivity, specifity, negative and positive predictive values were inferred using 
confusion matrix analyses. 
Results
Conclusion
 In our cohort the prevalence of OSA is relatively low compared to other studies, 
Probably due to the younger cohort and less severe obesity.
 Screening for OSA prior to bariatric surgery should be considered.
 Better screening algorithms are needed to identify patients at risk.
Study objective
Table 3: Demographics, AHI and factors predictive for OSA in men 
Table 2: Demographics, AHI and factors predictive for OSA in women 
Table 4: Receiver operator curves with cutoff values
Material and Methods
Results
Statistics
Variables 0-4.9 5-14.9 15-29.9 ≥30 5-14.9 15-29.9 ≥30 ≥5/h ≥15/h ≥30h
Age  36 (26-44)  43 (33-53) 46 (38-54) 46 (41-58) p<0.001 p<0.001 p<0.001 p<0.05 p>0.05 p<0.005
Female gender (%) 86 76 59 37 p>0.05 p<0.001 p<0.001 p>0.05 p>0.05 p>0.05
BMI 41.26 (37.76-44.99)  42.71 (39.08-45.39) 46.19 (39.56-51.65) 45.11 (14.50-49.70) p>0.05 p<0.005 p<0.001 p>0.05 p>0.05 p>0.05
Neck circumference (cm)  40.0 (37.3-42.0)  41.0 (40.0-45.0) 45.0 (41.5-47.5) 46.2 (43.8-48.0) p<0.005 p<0.001 p<0.001 p<0.05 p>0.05 p>0.05
FEV1 (l) 3.07 (2.74 -3.51)  2.98 (2.64-3.37) 2.83 (2.36-3.44) 3.00 (2.48-3.74) p>0.05 p>0.05 p>0.05
FVC(l) 3.83 (3.44-4.48) 3.76 (3.30-4.13) 3.58 (3.11-4.30) 4.02 (3.31-4.80) p>0.05 p>0.05 p>0.05
STOPBANG 3 (2-3) 3 (3-4) 4 (3-5) 5 (4-6) p<0.001 p<0.001 p<0.001 p>0.05 p>0.05 p>0.05
ESS 6 (4-9) 6 (4-10) 7 (4-9) 11 (7-14) p>0.05 p>0.05 p>0.05
FSS 3.11 (2.22-4.39) 4.00 (2.56-5.00) 3.33 (2.33-4.11) 4.89 (2.83-5.45) p>0.05 p>0.05 p<0.05
VAS (1-10) 5 (2-6) 3 (2-5) 4.0 (1.5-5.0) 5 (3-6) p>0.05 p>0.05 p>0.05
ODI (4%) 2.2 (1.0-3.9) 10.1 (6.9-12.9) 25.8 (20.2-29.8) 47.8 (41.6-74.2) p<0.001 p<0.001 p<0.001
SPO2 mean (%) 93.8 (93.0-94.9) 92.85 (91.80-94.00) 92.4 (90.3-93.5) 86.9 (89.3-91.1) p<0.05 p<0.001 p<0.001
SPO2<90% (min) 2.15 (0.30-16.55) 15.7 (5.1-42.2) 33.4 (18.2-165.2) 185.8 (89.8-260.5) p>0.05 p<0.001 p<0.001
AHI supine position 1.4 (0.3-3.3) 9.5 (5.2-15.1) 22.5 (14.2-37.5) 53.2 (24.4-66.9) p<0.001 p<0.001 p<0.001
PH 7.43 (7.42-7.45) 7.44 (7.42-7.45) 7.43 (7.42-7.45) 7.45 (7.43-7.45) p>0.05 p>0.05 p>0.05
PACO2 (mm Hg) 35 (32-37) 36.5 (34.5-38.0) 37 (34-39) 36 (34-39) p<0.05 p<0.05 p>0.05
HCO3- (mm Hg) 24.0 (23.0-24.8) 24.7 (23.8-25.4) 25.1 (24.2-25.9) 25.0 (23.1-26.4) p<0.001 p<0.005 p<0.005 p>0.05 p>0.05 p>0.05
PAO2 (mm Hg) 85.0 (79.1-92.0) 79.5 (71.5-86.5) 76.0 (70.0-86.0) 69.0 (63.0-75.5) p<0.001 p<0.001 p<0.001 p>0.05 p>0.05 p>0.05
Cholesterine 4.85 (4.16-5.60) 4.95 (4.32-5.63) 5.15 (4.50-5.71) 5.10 (4.27-5.64) p>0.05 p>0.05 p>0.05
HDL 1.27 (1.08-1.50) 1.20 (0.96-1.39) 1.22 (1.14-1.46) 1.13 (1.01-1.25) p<0.05 p>0.05 p<0.05
LDL 2.90 (2.34-3.59) 3.04 (2.49-3.68) 3.11  (2.50-3.65) 2.91 (2.49-3.52) p>0.05 p>0.05 p>0.05
Triglicyeride 1.24 (0.93-1.65) 1.45 (1.02-2.01) 1.47 (1.08-1.81) 1.70 (1.26-2.28) p>0.05 p<0.05 p<0.001
TSH 2.03 (1.44-2.97) 1.86 (1.34-2.69) 1.97 (1.63-2.85) 2.31 (1.93-3.12) p>0.05 p>0.05 p>0.05
Cortisol 284 (208-408) 298 (230-396) 374 (292-474) 346 (272-436) p>0.05 p<0.05 p>0.05
Oestradiol 162 (95-340) 108 (69-190) 104 (52-119) 108 (79-187) p<0.05 p<0.05 p>0.05
LH 5.6 (3.5-8.2) 7.1 (4.2-19.1) 6.6 (4.8-11.9) 5.2 (3.7-7.3) p<0.05 p>0.05 p>0.05
FSH 5.10 (3.55-7.45) 7.10 (3.80-25.00) 7.80 (4.10-19.80) 5.80 (5.00-9.00) p<0.001 p>0.05 p>0.05
HbA1c 5.55 (5.30-5.80) 5.80 (5.50-6.50) 5.90 (5.55-6.60) 6.30 (5.90-7.95) p<0.01 p<0.05 p<0.001 p>0.05 p>0.05 p>0.05
Arterial hypertension (n) 45 28 13 17 p>0.05 p>0.05 p<0.005
Coronary artery disease (n) 0 2 0 0 p>0.05 p>0.05 p>0.05
Cardiac arrythmia (n) 1 0 2 1 p>0.05 p>0.05 p>0.05
Diabetes mellitus (n) 14 15 11 11 p<0.005 p<0.005 p<0.001
COPD/Asthma (n) 14 3 5 6 p>0.05 p>0.05 p>0.05
Cerebrovascular disease (n) 6 1 1 4 p>0.05 p>0.05 p>0.05
Gastroesophageal reflux disease (n) 46 10 9 7 p>0.05 p>0.05 p>0.05
Dyslipidemia (n) 30 27 13 8 p<0.01 p<0.001 p>0.05
Psychiatric disease (n) 55 18 8 9 p>0.05 p>0.05 p>0.05
Smoker (n) 28 17 5 3 p>0.05 p>0.05 p>0.05
Former smoker (n) 12 6 2 4 p>0.05 p>0.05 p>0.05
AHI Univariate p-value Multivariate p-value
Table 1: Patient demographics, AHI and factors predictive for OSA
Variables 0-4.9 5-14.9 15-29.9 ≥30 5-14.9 15-29.9 ≥30 ≥5/h ≥15/h
Age 36 (26-44) 42 (31-54) 50 (38-55) 47 (43-49) p<0.005 p<0.001 p<0.005 p>0.05 p>0.05
BMI 41.26 (38.03-44.90) 42.64 (39.15-45.10) 45.91 (39.56-48.61) 48.62 (42.10-54.36) p>0.05 p>0.05 p<0.001 p>0.05 p>0.05
Neck circumference (cm) 39 (37-41) 40 (39-41) 43 (41-44.5) 43.5 (43-44.0) p>0.05 p<0.001 p<0.001 p>0.05 p>0.05
FEV1 (l) 3.01 (2.64-3.38) 2.78 (2.49-3.10) 2.46 (2.35-2.86) 2.74 (2.27-2.89) p<0.01 p<0.001 p>0.05 p>0.05 p>0.05
FVC(l) 3.74 (3.36-4.25) 3.53 (3.10-3.94) 3.19 (2.58-3.58) 3.28 (3.05-3.67) p<0.01 p<0.001 p<0.05 p>0.05 p>0.05
STOPBANG 2 (2-3) 3 (2-4) 4 (2-5) 5 (4-5) p<0.005 p<0.001 p<0.001 p>0.05 p>0.05
ESS 6 (4-9) 6 (4-10) 6 (2.5-9) 7 (6-12) p>0.05 p>0.05 p>0.05
FSS 3.11 (2.22-4.39) 4 (1.95-4.56) 3.33 (2.33-4.33) 5.06 (1.78-6.11) p>0.05 p>0.05 p>0.05
VAS (1-10) 5 (2-6) 2.5 (2-5) 4 (1.3-5) 5 (5-6) p>0.05 p>0.05 p>0.05
ODI (4%) 2 (1-4) 10 (7-14) 23 (18-28) 58 (36-83) p>0.05 p<0.001 p<0.001
SPO2 mean (%) 93.8 (93.0-94.9) 92.9 (91.8-94.0) 92.4 (90.3-93.5) 89.3 (86.9-91.1) p<0.001 p<0.005 p<0.001
SPO2<90% (min) 2 (1-17) 16 (5-42) 33 (18-165) 186 (90-260) p<0.001 p<0.001 p<0.001
AHI supine position 1.4 (0.3-3.4) 9.6 (5.3-15.4) 26.9 (16.9-29.8) 42.8 (29.2-72.1) p<0.001 p<0.001 p<0.001
PH 7.44 (7.42-7.46) 7.44 (7.43-7.45) 7.44 (7.42-7.45) 7.46 (7.45-7.46) p>0.05 p>0.05 p>0.05
PACO2 (mm Hg) 34 (32-36) 36 (34-36) 36 (34-38) 35 (34-36) p>0.05 p<0.05 p>0.05
HCO3- (mm Hg) 23.80 (22.90-24.65) 24.70 (23.80-26.60) 25.10 (24.1-25.90) 25.10 (22.50-26.20) p<0.001 p<0.01 p>0.05 p>0.05 p>0.05
PAO2 (mm Hg) 86 (81-92) 80 (74-88) 80 (75-87) 70 (64-72) p<0.001 p<0.05 p<0.001 p>0.05 p>0.05
Cholesterine 4.84 (4.11-5.61) 4.95 (4.37-5.59) 4.96 (4.50-5.78) 5.10 (4.32-5.47) p>0.05 p>0.05 p>0.05
HDL 1.30 (1.11-1.56) 1.20 (0.98-1.37) 1.26 (1.22-1.49) 1.22 (1.05-1.49) p<0.01 p>0.05 p>0.05
LDL 2.87 (2.32-3.54) 3.05 (2.62-3.56) 3-07 (2.46-3.48) 2.98 (2.78-3.57) p>0.05 p>0.05 p>0.05
Triglicyeride 1.22 (0.86-1.54) 1.44 (1.01-1.84) 1.46 (1.07-1.72) 1.42 (1.15-1.70) p>0.05 p<0.01 p>0.05
TSH 2.02 (1.45-2.98) 1.86 (1.33-2.71) 2.16 (1.65-2.60) 2.86 (1.93-3.59) p>0.05 p>0.05 p>0.05
Cortisol 286 (212-423) 284 (223-399) 400 (257-628) 321 (218-422) p>0.05 p<0.05 p>0.05
Oestradiol 199 (107-357) 92 (66-183) 400 (44-149) 124 (80-211) p>0.05 p>0.05 p>0.05
LH 5.70 (3.15-9.55) 11.7 (4.7-20.6) 8.9 (4.8-21.3) 5.05 (3.70-7.90) p<0.01 p>0.05 p>0.05
FSH 5.3 (3.7-7.5) 8.0 (5.4-36.6) 9.55 (4.05-38.7) 9.0 (4.6-11.1) p<0.001 p<0.05 p>0.05 p>0.05 p>0.05
HbA1c 5.5 (5.3-5.8) 5.70 (5.50-6.15) 6.00 (5.65-7.05) 6.25 (6.00-6.80) p<0.01 p<0.001 p<0.001 p>0.05 p>0.05
Arterial hypertension (n) 33 21 5 7 p<0.001 p>0.05 p<0.001
Coronary artery disease (n) 0 1 0 0 p>0.05 p>0.05 p>0.05
Cardiac arrythmia (n) 1 0 1 0 p>0.05 p>0.05 p>0.05
Diabetes mellitus (n) 11 3 4 1 p>0.05 p>0.05 p>0.05
COPD/Asthma (n) 11 3 4 1 p>0.05 p>0.05 p>0.05
Cerebrovascular disease (n) 5 1 1 0 p>0.05 p>0.05 p>0.05
Gastroesophageal reflux disease (n) 36 7 4 3 p>0.05 p>0.05 p>0.05
Dyslipidemia (n) 26 18 7 3 p<0.01 p>0.05 p>0.05
Psychiatric disease (n) 49 14 7 4 p>0.05 p>0.05 p>0.05
Smoker (n) 23 10 1 0 p>0.05 p>0.05 p>0.05
Former smoker (n) 11 4 1 1 p>0.05 p>0.05 p>0.05
AHI Univariate p-value Multivariate p-value
Variables 0-4.9 5-14.9 15-29.9 ≥30 5-14.9 15-29.9 ≥30 ≥5 ≥15 ≥30
Age 36 (25-43) 43 (40-50) 43 (38-49) 46 (37-58) p>0.05 p>0.05 p<0.001 p>0.05 p>0.05 p>0.05
BMI 40.62 (36.54-45.98) 43.42 (39.08-48.84) 46.73 (39.68-52.64) 42.52 (41.03-48.44) p>0.05 p>0.05 p>0.05
Neck circumference (cm) 45.5 (43-49) 45.8 (44-50) 48 (46-50) 47 (46.3-49) p>0.05 p>0.05 p>0.05
FEV1 (l) 3.90 (3.06-4.25) 3.49 (3.28-3.97) 3.67 (2.97-4.03) 3.46 (2.81-3.96) p>0.05 p>0.05 p>0.05
FVC(l) 4.83 (4.17-5.63) 4.51 (4.10-4.88) 4.65 (3.93-5.49) 4.58 (3.71-5.06) p>0.05 p>0.05 p>0.05
STOPBANG 5 (4-6) 4 (4-6) 5 (3.5-5) 4 (5-6) p>0.05 p>0.05 p>0.05
ESS 6 (5-8) 8 (5-14) 8.5 (7-9) 11.5 (7-14) p>0.05 p>0.05 p<0.005 p>0.05 p>0.05 p>0.05
FSS 3.84 (2.56-4.56) 4.67 (3.45-5.45) 3.33 (2.39-3.78) 4.86 (3.22-5.33) p>0.05 p>0.05 p>0.05
VAS (1-10) 3 (3-5) 5 (2.5-6.5) 4 (1.5-5) 5 (2-6) p>0.05 p>0.05 p>0.05
SPO2 mean (%) 93.8 (92.6-94.5) 93.0 (91.9-94.9) 92.01 (89.3-93.1) 89.4 (86.8-91) p>0.05 p>0.05 p<0.001
SPO2<90% (min) 5 (1-34) 16 (3-22) 39 (25-185) 166 (73-266) p>0.05 p>0.05 p<0.001
AHI supine position 2.4 (0.9-3.3) 9.2 (3.2-13.9) 20.7 (11.0-43) 56 (9.1-65.5) p>0.05 p<0.005 p<0.001
PH 7.43 (7.42-7.45) 7.42 (7.41-7.43) 7.43 (7.42-7.45) 7.44 (7.42-7.45) p<0.05 p>0.05 p>0.05
PACO2 (mm Hg) 37 (37-39) 38 (36-41) 38 (35-39) 37 (34-40) p>0.05 p>0.05 p>0.05
HCO3- (mm Hg) 24.55 (23.9-24.45) 24.5 (23.6-25.4) 25.05 (24.35-25.75) 26 (23.6-26.6) p>0.05 p>0.05 p>0.05
PAO2 (mm Hg) 78 (70-89) 75 (69-79) 71 (65-78) 66 (60-78) p>0.05 p>0.05 p<0.05
Cholesterine 5.26 (4.30-5.54) 4.95 (4.23-5.63) 5.24 (4.63-5.59) 5.04 (4.22-5.79) p>0.05 p>0.05 p>0.05
HDL 1.07 (0.97-1.24) 1.07 (0.83-1.38) 1.20 (1-1.38) 1.11 (0.96-1.17) p>0.05 p>0.05 p>0.05
LDL 3.16 (2.58-3.76) 2.89 (2.42-4.30) 3.47 (2.87-3.65) 2.86 (2.44-.50) p>0.05 p>0.05 p>0.05
Triglicyeride 1.59 (1.14-2.89) 1.46 (1.15-2.61) 1.54 (1.16-2.02) 2.22 (1.27-2.51) p>0.05 p>0.05 p>0.05
TSH 2.05 (1.38-2.28) 1.86 (1.37-2.52) 1.80 (1.61-3.18) 2.30 (1.89-2.78) p>0.05 p>0.05 p>0.05
Cortisol 280 (193-160) 328 (288-364) 371 (316-424) 356 (331-476) p>0.05 p>0.05 p<0.05 p>0.05 p>0.05 p>0.05
Oestradiol 103 (82-134) 123 (85-176) 104 (84-109) 94 (78-177) p>0.05 p>0.05 p>0.05
LH 5.25 (4.40-6.15) 4.2 0(2.70-6.60) 6.20 (4.75-7.95) 5.20 (3.70-6.70) p>0.05 p>0.05 p>0.05
FSH 4.05 (2.90-6.90) 3.7 (2.4-5.3) 5.50 (3.55-10.10) 5.50 (5.0-6.3) p>0.05 p>0.05 p>0.05
HbA1c 5.55 (5.30-5.80) 5.80 (5.5-6.5) 5.90 (5.55-6.60) 6.30 (5.90-7.95) p>0.05 p>0.05 p>0.05
Arterial hypertension (n) 12 7 8 10 p>0.05 p>0.05 p>0.05
Coronary artery disease (n) 0 1 0 0 p>0.05 p>0.05 p>0.05
Cardiac arrythmia (n) 0 0 1 1 p>0.05 p>0.05 p>0.05
Diabetes mellitus (n) 6 6 2 6 p>0.05 p>0.05 p>0.05
COPD/Asthma (n) 3 0 1 5 p>0.05 p>0.05 p>0.05
Cerebrovascular disease (n) 1 0 0 4 p>0.05 p>0.05 p>0.05
Gastroesophageal reflux disease (n) 10 3 5 4 p>0.05 p>0.05 p>0.05
Dyslipidemia (n) 4 9 6 5 p<0.05 p>0.05 p>0.05
Psychiatric disease (n) 6 4 1 5 p>0.05 p>0.05 p>0.05
Smoker (n) 5 7 4 3 p>0.05 p>0.05 p>0.05
Former smoker (n) 1 2 1 3 p>0.05 p>0.05 p>0.05
AHI Univariate p-value Multivariate p-value
Cutoff Sensitivity Specifity PPV NPV
AHI>5/h
Age (y) overall 40 0,63 0,63 0,56 0,69
Age (y) Female 40 0,59 0,62 0,46 0,74
Age (y) Male 41 0,67 0,75 0,85 0,52
Neck Circumference (cm) overall 40 0,86 0,47 0,55 0,82
Neck Circumference (cm) Female 40,2 0,57 0,63 0,44 0,74
Neck Circumference (cm) Male 46,5 0,63 0,61 0,78 0,42
BMI overall 42,41 0,58 0,62 0,53 0,66
BMI Female 40 0,78 0,54 0,47 0,82
BMI Male 41,67 0,65 0,60 0,78 0,44
STOPBANG overall 4 0,63 0,77 0,68 0,73
STOPBANG Female 4 0,46 0,84 0,62 0,73
STOPBANG Male 5 0,60 0,36 0,70 0,26
ESS overall 9 0,42 0,73 0,55 0,62
ESS Female 7 0,42 0,53 0,33 0,62
ESS Male 8 0,66 0,69 0,85 0,43
FSS overall 3,44 0,58 0,56 0,50 0,64
FSS Female 3,33 0,60 0,54 0,41 0,72
FSS Male 4,11 0,52 0,50 0,73 0,29
AHI>15/h
Age (y) overall 43 0,64 0,64 0,32 0,87
Age (y) Female 43 0,70 0,64 0,23 0,93
Age (y) Male 42 0,62 0,59 0,56 0,65
Neck Circumference (cm) overall 43 0,82 0,73 0,45 0,94
Neck Circumference (cm) Female 42,41 0,63 0,85 0,38 0,94
Neck Circumference (cm) Male 45,28 0,88 0,50 0,59 0,84
BMI overall 45,71 0,52 0,80 0,41 0,86
BMI Female 45,54 0,59 0,81 0,33 0,93
BMI Male 44,54 0,55 0,65 0,57 0,63
STOPBANG overall 4 0,79 0,70 0,42 0,92
STOPBANG Female 4 0,69 0,80 0,38 0,94
STOPBANG Male 5 0,73 0,48 0,53 0,68
ESS overall 7 0,62 0,54 0,26 0,84
ESS Female 7 0,44 0,54 0,14 0,86
ESS Male 7 0,82 0,50 0,58 0,76
FSS overall 3,44 0,53 0,50 0,21 0,81
FSS Female 3,33 0,60 0,51 0,15 0,90
FSS Male 4,11 0,45 0,43 0,41 0,48
AHI>5, STOPBANG≥ 3
HCO3 overall 24,55 0,57 0,59 0,63 0,52
HCO3 Female 24,56 0,57 0,65 0,60 0,63
HCO3 Male 25,08 0,40 0,57 0,70 0,28
AHI>5 STOPBANG≥ 4
HCO3 overall 24,7 0,59 0,54 0,73 0,38
HCO3 Female 24,56 0,57 0,65 0,60 0,63
HCO3 Male 24,37 0,60 0,51 0,34 0,75
AHI>15, STOPBANG≥3
HCO3 overall 24,55 0,57 0,53 0,34 0,75
HCO3 Female 24.56 0.57 0.65 0.59 0.62
HCO3 Male 24,2 0,73 0,33 0,47 0,60
AHI>15 STOPBANG≥ 4
HCO3 overall 24,8 0,53 0,55 0,47 0,61
HCO3 Female 25,8 0,85 0,39 0,68 0,64
HCO3 Male 24,04 0,70 0,38 0,48 0,60
